JP2017517553A - 掻痒の治療方法 - Google Patents

掻痒の治療方法 Download PDF

Info

Publication number
JP2017517553A
JP2017517553A JP2016572657A JP2016572657A JP2017517553A JP 2017517553 A JP2017517553 A JP 2017517553A JP 2016572657 A JP2016572657 A JP 2016572657A JP 2016572657 A JP2016572657 A JP 2016572657A JP 2017517553 A JP2017517553 A JP 2017517553A
Authority
JP
Japan
Prior art keywords
nalbuphine
day
dose
sustained release
pruritus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016572657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517553A5 (enExample
Inventor
トーマス シャーシャ
トーマス シャーシャ
Original Assignee
トレビ セラピューティクス インコーポレイテッド
トレビ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレビ セラピューティクス インコーポレイテッド, トレビ セラピューティクス インコーポレイテッド filed Critical トレビ セラピューティクス インコーポレイテッド
Publication of JP2017517553A publication Critical patent/JP2017517553A/ja
Publication of JP2017517553A5 publication Critical patent/JP2017517553A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016572657A 2014-06-13 2015-06-12 掻痒の治療方法 Pending JP2017517553A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011936P 2014-06-13 2014-06-13
US62/011,936 2014-06-13
PCT/US2015/035650 WO2015192071A1 (en) 2014-06-13 2015-06-12 Methods for treating pruritus

Publications (2)

Publication Number Publication Date
JP2017517553A true JP2017517553A (ja) 2017-06-29
JP2017517553A5 JP2017517553A5 (enExample) 2018-06-28

Family

ID=54834447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572657A Pending JP2017517553A (ja) 2014-06-13 2015-06-12 掻痒の治療方法

Country Status (12)

Country Link
US (2) US20150359789A1 (enExample)
EP (1) EP3154546A4 (enExample)
JP (1) JP2017517553A (enExample)
KR (1) KR20170016983A (enExample)
CN (1) CN106535897A (enExample)
AU (1) AU2015274327A1 (enExample)
BR (1) BR112016029236A2 (enExample)
CA (1) CA2951420A1 (enExample)
IL (1) IL249475A0 (enExample)
MX (1) MX2016016404A (enExample)
RU (1) RU2017101102A (enExample)
WO (1) WO2015192071A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525225A (ja) * 2018-03-29 2021-09-24 ルモサ セラピューティクス カンパニー， リミテッド 掻痒症を治療するための組成物及び方法
US11660296B2 (en) 2018-07-23 2023-05-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
US12274696B2 (en) 2020-01-10 2025-04-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
EP3432871B1 (en) * 2016-03-21 2023-11-15 Trevi Therapeutics, Inc. Treatment of uremic pruritus
EP3532061A4 (en) * 2016-10-25 2020-07-08 Trevi Therapeutics, Inc. TREATMENT OF PRURIGO NODULAR
AU2019301134A1 (en) * 2018-07-11 2021-01-21 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506059A (ja) * 2005-08-24 2009-02-12 ペンウエスト ファーマシューティカルズ カンパニー ナルブフィンの徐放性製剤
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
EP2150247B1 (en) * 2007-04-23 2012-10-31 Symrise AG Polyethylene glycol esters and cosmetic and/or dermatological preparations
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) * 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506059A (ja) * 2005-08-24 2009-02-12 ペンウエスト ファーマシューティカルズ カンパニー ナルブフィンの徐放性製剤
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Efficacy of intramuscular nalbuphine versus diphenhydramine for the prevention of epidural morphine-", CHANG GUNG MEDICAL JOURNAL, vol. 34(2):172-178, JPN7019000711, 2011, ISSN: 0004165112 *
"Optimal dose of nalbuphine for treatment of intrathecal-molphine induced pruritus after caesarean se", THE JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, vol. 25(3):209-213, JPN7019000712, June 1999 (1999-06-01), ISSN: 0004165113 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525225A (ja) * 2018-03-29 2021-09-24 ルモサ セラピューティクス カンパニー， リミテッド 掻痒症を治療するための組成物及び方法
US11660296B2 (en) 2018-07-23 2023-05-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
US12274696B2 (en) 2020-01-10 2025-04-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Also Published As

Publication number Publication date
US20190099416A1 (en) 2019-04-04
AU2015274327A1 (en) 2017-01-05
KR20170016983A (ko) 2017-02-14
CA2951420A1 (en) 2015-12-17
EP3154546A1 (en) 2017-04-19
MX2016016404A (es) 2017-11-30
BR112016029236A2 (pt) 2017-11-07
EP3154546A4 (en) 2018-01-10
WO2015192071A1 (en) 2015-12-17
RU2017101102A (ru) 2018-07-16
IL249475A0 (en) 2017-02-28
RU2017101102A3 (enExample) 2019-01-28
US20150359789A1 (en) 2015-12-17
CN106535897A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
JP7072280B2 (ja) 抗そう痒剤
US20250032480A1 (en) Methods for treating pruritus
JP2017517553A (ja) 掻痒の治療方法
US8987289B2 (en) Methods for treating pruritus
US8637538B1 (en) Methods for treatment of pruritis
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
EP3432871B1 (en) Treatment of uremic pruritus
EP3532061A1 (en) Treatment of prurigo nodularis
HK40013011A (en) Methods for treating pruritus
HK1215541B (en) Methods for treating pruritus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191202